Reata Pharmaceuticals, Inc.: Series D $78M

Posted in I - Series D, Q - 3Q10, R - SOUTH WEST, X - Inflammation, X - Renal, XX - TX

Reata Pharmaceuticals (Irving, TX) a clinical-stage small molecule company focused on inflammation modulation in chronic kidney disease, closed a $78M Series D financing. Participants include CPMG and Novo Ventures.

Jul

2010

Action Pharma, A/S: Series C $6.3M

Posted in I - Series C, Q - 2Q10, R - INTERNATIONAL, X - Inflammation, X - Renal

Action Pharma (Denmark) a clinical-stage biopharmaceutical company focused on acute kidney injury in patients undergoing cardiac surgery and inflammation, closed a $6.3M Series C financing. Participants include Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital.

Feb

2010

Evolva, SA: Series B $15.3M

Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Cardiology, X - Renal, X - Synthetic Biology

Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $15.2M Series B financing bringing the total round up to $42.3M. Participants include Wellington Partners, Aravis Venture Associates, Auriga Partners and Vinci Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Dec

2009

Evolva, SA: Series B $27.5M

Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Cardiology, X - Renal, X - Synthetic Biology

Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $27,5M Series B financing. Participants include Wellington Partners Venture Capital, Aravis Venture Associates, Auriga Partners and Vinci Capital.

Jun

2009

Proteon Therapeutics, Inc.: Series B $12M

Posted in I - Series B, Q - 2Q09, R - NORTH EAST, X - Hemodialysis, X - PAD, X - Renal, X - Vascular, XX - MA

Proteon Therapeutics (Waltham, MA) a clinical-stage biopharmaceutical company focused on a recombinant human elastase designed to improve arteriovenous fistula surgery outcomes in patients requiring chronic hemodialysis, closed on $12M, bringing the total Series B financing to $50M. Participants include Bessemer Venture Partners, Devon Park Bioventures, MPM Bio, Vectis Healthcare & Life Science Fund, TVM Capital, [...]

Mar

2009

Proteon Therapeutics, Inc.: Series B $38M

Posted in I - Series B, Q - 1Q09, R - NORTH EAST, X - Renal, X - Vascular, XX - MA

Proteon Therapeutics (Waltham, MA) a clinical stage biopharmaceutical company focused on renal and vascular disease, closed a $38M Series B financing. Participants include MPM Capital, Vectis Healthcare & Life Sciences Fund, TVM Capital, Skyline Ventures, Prism VentureWorks and Intersouth Partners.

Mar

2009

Ardian, Inc.: Series C $47M

Posted in I - Series C, Q - 1Q09, R - WEST, X - Cardiology, X - Device (Catheter), X - Renal, XX - CA

Ardian (Palo Alto, CA) a clinical-stage medical device company focused on catheter-based treatment for hypertension, chronic kidney disease and heart failure, closed a $47M Series C financing. Participants include Medtronic, Emergent Medical Partners, Advanced Technology Ventures, Morgenthaler Ventures and Split Rock Partners.

Dec

2008

Infacare Pharmaceutical Corp.: Series B $28M

Posted in I - Series B, Q - 4Q08, R - NORTH EAST, X - Pediatric, X - Renal

Infacare Pharmaceutical (Trevose, PA) a specialty pharma company focused on the the acute neonatal and pediatric care closed a $28M Series financing. Participants include HealthCare Ventures, Longitude Capital, FirstMark Capital and Atlas Venture.

Dec

2008

AlloCure, Inc.: Series A $14.5M

Posted in I - Series A, Q - 3Q08, R - ROCKY MOUNTAIN, X - Renal

AlloCure (Germany, UT) a cell therapy company focused on acute kidney injury closed a $14.5M Series A financing. Participants include SV Life Sciences and Novo AS.

Dec

2008

Cytochroma, Inc.: Series C $45M

Posted in I - Series C, Q - 3Q08, R - INTERNATIONAL, X - Renal

Cytochroma (Canada) clinical-stage specialty pharmaceutical company focused on products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease, closed a $45M Series C financing. Participants include Mitsubishi Tanabe Pharma Corporation, Vengrowth Advanced Life Sciences Fund, Caisse de Depot et Placement du Quebec, Novo, Canadian Medical Discoveries Fund, T2C2 Capital, GrowthWorks Canadian Fund, [...]

« Previous Entries

to top of page...